GENTAK- gentamicin sulfate ointment

Gentak by

Drug Labeling and Warnings

Gentak by is a Prescription medication manufactured, distributed, or labeled by A-S Medication Solutions. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • INDICATIONS AND USAGE

    Gentamicin sulfate ophthalmic ointment is indicated in the topical treatment of ocular bacterial infections including conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharonconjunctivitis: acute meibomianitis, and dacryocystitis, caused by susceptible strains of the following microorganisms:

  •   Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens.
  • CONTRAINDICATIONS

    Gentamicin sulfate ophthalmic ointment is con-traindicated in patients with known hypersensitivity to any of the components.

  • WARNINGS

    NOT FOR INJECTION INTO THE EYE.

    Gentamicin sulfate ophthalmic ointment is not for injection. It should never be injected subconjunctivally, nor should it be directly introduced into the anterior chamber of the eye.

  • PRECAUTIONS

    General: Prolonged use of topical antibiotics may give rise to overgrowth of nonsusceptible organisms including fungi. Bacterial resistance to gentamicin may also develop. If purulent discharge, inflammation or pain becomes aggravated, the patient should discontinue use of the medication and consult a physician.

    If irritation or hypersensitivity to any component of the drug develops, the patient should discontinue use of this preparation and appropriate therapy should be instituted.

    Ophthalmic ointments may retard corneal healing.

    Information for patients: To avoid contamination, do not touch tip of container to the eye, eyelid or any surface.

    Carcinogenesis, Mutagenesis, Impairment of Fertility: There are no published carcinogenicity or impairment of fertility studies on gentamicin. Aminoglycoside antibiotics have been found to be non-mutagenic.

    Pregnancy: Pregnancy Category C. Gentamicin has been shown to depress body weights, kidney weights and median glomerular counts in newborn rats when administered systemically to pregnant rats in daily doses approximately 500 times the maximum recommended ophthalmic human dose. There are no adequate and well-controlled studies in pregnant women. Gentamicin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

    Pediatric Use: Safety and effectiveness in neonates have not been established.

  • ADVERSE REACTIONS

    Bacterial and fungal corneal ulcers have developed during treatment with gentamicin ophthalmic preparations.

    The most frequently reported adverse reactions are ocular burning and irritation upon drug instillation, non-specific conjunctivitis, conjunctival epithelial defects and conjunctival hyperemia.

    Other adverse reactions which have occurred rarely are allergic reactions, thrombocytopenic purpura and hallucinations.

  • DOSAGE AND ADMINISTRATION

    Apply a small amount (approximately 1/2 inch ribbon) of ointment to the affected eye(s) two or three times a day.

  • HOW SUPPLIED

    Product: 50090-0251

    NDC: 50090-0251-0 3.5 g in a TUBE / 1 in a CARTON

  • Gentamicin Sulfate

    Label Image
  • INGREDIENTS AND APPEARANCE
    GENTAK 
    gentamicin sulfate ointment
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 50090-0251(NDC:17478-284)
    Route of AdministrationOPHTHALMIC
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    GENTAMICIN SULFATE (UNII: 8X7386QRLV) (GENTAMICIN - UNII:T6Z9V48IKG) GENTAMICIN3 mg  in 1 g
    Inactive Ingredients
    Ingredient NameStrength
    Methylparaben (UNII: A2I8C7HI9T) 0.5 mg  in 1 g
    Propylparaben (UNII: Z8IX2SC1OH) 0.1 mg  in 1 g
    Petrolatum (UNII: 4T6H12BN9U)  
    Mineral Oil (UNII: T5L8T28FGP)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 50090-0251-01 in 1 CARTON06/29/2016
    13.5 g in 1 TUBE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA06409305/08/2006
    Labeler - A-S Medication Solutions (830016429)
    Establishment
    NameAddressID/FEIBusiness Operations
    A-S Medication Solutions830016429RELABEL(50090-0251)

  • Trademark Results [Gentak]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    GENTAK
    GENTAK
    76454682 2755775 Dead/Cancelled
    KMG ELECTRONIC CHEMICALS, INC.
    2002-10-02
    GENTAK
    GENTAK
    73652684 1464244 Live/Registered
    AKORN, INC.
    1987-04-02

    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.